JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)- Therapeutic Core

项目总结-治疗核心 HIV感染者中存在的多种CNS合并症需要采取更全面的方法， 开发新的HIV神经疗法为了应对这些挑战，JHU促进中心 艾滋病毒神经治疗（JHU CAHN）将发展成为一个综合性的研究中心，针对所有方面 与PWH相关的CNS并发症。治疗核心的主要目标是作为一个 专门的药物发现单位，并通过与其他JHU CAHN密切合作开发新的疗法 核心，以及接触研究人员内外的神经艾滋病病毒，包括那些 NIMH的其他NeuroHIV中心和工业部门。这一雄心勃勃的目标将通过以下方式实现： 一个经验丰富的药物发现工作人员监督四个关键职能建立在治疗 核心，即药物化学、试验开发/筛选、药物代谢和药代动力学， 动物药理学/毒理学。集体药物发现相关资源将被定向到 参与NeuroHIV转化研究的研究人员，重点是早期研究人员， 代表少数民族和艾滋病毒的新调查人员。针对药物滥用的多学科结构 发现研究还允许核心提供广泛的药物发现培训和教育 机会（例如，实习、研究金、学士后和研究生培训、药物发现和 翻译课程）。此外，治疗核心是独特的定位，以促进认识， 通过利用核心的广泛网络，在工业部门中解决HIV相关的CNS并发症 多年来通过多个学术生物制药合作伙伴关系建立。与各中心密切合作， 生物标志物，临床和开发核心，治疗核心准备抓住这一机会， 实现以下三个具体目标：（目标1）建立药物发现平台， PWH中枢神经系统并发症的新疗法;（目的2）评价目的1药物的疗效 在HIV小鼠模型中的神经行为表型;（目标3）提供药物发现教育 为学术界服务。与生物制药公司合作，研究艾滋病毒的新疗法 合并症。

PROJECT SUMMARY – THERAPEUTIC CORE The multiple CNS comorbidities present in HIV-infected individuals necessitate a more holistic approach in advancing new HIV neurotherapeutics. In line with these challenges, the JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN) will evolve into a comprehensive research center targeting all aspects of CNS complications associated with PWH. The main objective of the Therapeutic Core is to serve as a dedicated drug discovery unit and to develop new therapeutics by working closely with other JHU CAHN cores as well as reaching out to investigators both in and outside the field of NeuroHIV including those affiliated with other NIMH NeuroHIV centers and the industrial sector. This ambitious goal will be enabled by a highly experienced drug discovery staff overseeing four key functions established within the Therapeutic Core, namely, medicinal chemistry, assay development/screening, drug metabolism and pharmacokinetics, and animal pharmacology/toxicology. The collective drug discovery-related resources will be directed toward investigators involved in NeuroHIV translational research, with a focus on early-stage investigators, under- represented minorities, and investigators new to HIV. The multidisciplinary structure tailored to drug discovery research also allows the core to provide a wide range of drug discovery training and educational opportunities (e.g., internships, fellowships, post-baccalaureate and graduate training, drug discovery and translational courses). Furthermore, the Therapeutic Core is uniquely positioned to promote awareness of HIV-related CNS complications among the industry sector by taking advantage of core’s extensive network built over years through multiple academic-biopharma partnerships. Working closely with the centers’ Biomarker, Clinical, and Developmental cores, the Therapeutic Core is poised to seize this opportunity by executing the following three Specific Aims: (Objective 1) Establish a drug discovery platform to develop novel therapeutics for CNS complications in PWH; (Objective 2) Evaluate drugs from Objective 1 for effect on neurobehavioral phenotypes in murine models of HIV; (Objective 3) Provide drug discovery education and services to the academic community. Engage with biopharma to investigate novel therapeutics for HIV comorbidities.